成人急性白血病におけるアクラシノマイシンの粘膜障害について　　ＢＨ‐ＡＣ・ＡＭＰ療法とＢＨ‐ＡＣ・ＤＭＰ療法の比較検討:—BH-AC·AMP療法とBH-AC·DMP療法の比較検討—

概要

論文の詳細を見る
Aclacinomycin A (ACM) is different from other anthracycline antibiotics in the antitumor activity and clinical effect. As compared with daunomycin and adriamycin, ACM is less cardiotoxic and drug induced alopecia is very mild.A comparison studies of clinical effects and side effects of combination chemotherapies, BH-AC·AMP (behenoyl-ara-C, aclacinomycin A, 6-mercaputopurine, prednisolone) and BH-AC·DMP (behenoyl-ara-C, daunomycin, 6-mercaputopurine, prednisolone) on cases with adult acute leukemia were done. Twelve patients were treated with BH-AC·AMP (AMP) therapy and thirteen patients were treated with BH-AC·DMP (DMP) therapy. The AMP therapy is effective in patients not responding to the DMP therapy. However, in about half of 12 cases receiving AMP therapy we noticed severe bleeding in the urinary tract, genital organ and alimentary tract. These side effects were more frequent and severe in the AMP therapy than the DMP therapy. Care should therefore be taken with regard to mucosal injury when ACM is used.
一般社団法人日本血液学会の論文